Investment Opportunity

Major New Discoveries Could Bring Huge Rewards For Juva Life

Juva Life Inc | Listed on: CSE:JUVA  |  OTCQB:JUVAF | JUVA.CN | JUVAF

Juva Life is a Canadian company that is set to revolutionize the healthcare industry. They are bringing together the latest tools in biology, medicine and technology to develop natural products formulated from molecular entities found in cannabis that offer evidence-based, positive effects against many of our most challenging health conditions.

Why You Should Consider Investing

  • Revolutionary new discoveries

    Juva Life’s discovery of patented new molecules positioned to revolutionize the enormous market for anti-inflammatory products.

  • An accelerated and innovative approach

    Juva Life’s product development incurs a fraction of the cost, time, and risk of traditional clinical pathways.

  • The perfect operations team

    Juva Life’s operations led by a team of MJ visionaries, both on the business and scientific sides.

  • Ongoing Research & Development

    Juva Life’s product R&D funded by vertically integrated retail operations including cultivation and distribution facilities.

  • Targeted strategy

    Targeting large pharma takeout or key licensing agreements over medium term, opening the door to immense value creation.

  • Perfect time to invest

    The wider market has yet to catch on to the significance of major anti-inflammatory discoveries.

Read our free report to find out why you should invest in Juva Life right now before the wider market learns of its game-changing discoveries.

Find out more

Major New Discoveries Could Bring Huge Rewards for Juva Life

.

Inflammation is a common immune system response, but it’s often also the initial cause of a wide variety of ailments, including heart disease, diabetes, kidney trouble and even many forms of cancer. 

It’s why paracetamol and ibuprofen are so widely used worldwide, as they are thought to help reduce inflammation and prevent more serious ailments from developing. But, many over-the-counter and prescribed options that contain anti-inflammatories are in fact very weak - worse still, they can be toxic, too.

That’s where Juva Life come in, and why they present an excellent opportunity for savvy investors. Juva Life is poised to help medical science take a huge leap forward in preventing diseases related to inflammation. 

In fact, Juva Life’s discoveries could be among the scientific world's most important in recent years. If that sounds hyperbolic, consider it’s estimated that around 50% of all deaths worldwide are caused by inflammation-related diseases.

The anti-inflammation industry is already huge - and it’s growing, too.  according to Global Industry Analytics, it's poised to reach a $131 billion valuation within just five years. This means Juva Life could become an incredibly lucrative proposition for investors.

The surprise behind the discoveries

Juva Life's discoveries in this enormous market were actually made while researching the therapeutic effects of cannabis. Juva Life is at home in the cannabis industry, having already developed cultivation and production sites. However, it has also been researching the therapeutic implications of cannabis behind the scenes.

This work resulted in the discovery of two entirely new molecules known as JUVA-019 and JUVA-041. Data has shown these molecules to be extremely effective at inhibiting the proteins that can cause inflammation.

Testing is underway to optimize JUVA-019 and JUVA-041's use, seeing how they react when mixed with other compounds to create the most effective versions possible.

Also, both are derived from natural compounds and neither are terpenes or cannabinoids. This means they are both less toxic than alternatives and less exposed to the normal regulatory barriers cannabis products face.

Read our exclusive deep dive into the ground-breaking discoveries that could see Juva Life help billions worldwide while making huge profits in the process.

.

A quicker route to market puts Juva Life on an accelerated path to success

.

The fact that regulation will be much easier for Juva Life is a huge boost. But it’s not the only obstacle that the company is poised to navigate with much greater ease than most.

Juva Life is already an established company with strong fundamentals and experience in the cannabis sector. This means much of the funding a start-up would need is already there. Furthermore, the business is able to leverage many of its current assets to help fund further research and development.

Its recreational arm, for example, is generating millions of dollars of revenue annually. This simply affords the business financial backup that other companies on its path just wouldn’t have.

Indeed, CEO Doug Chloupek - a trailblazer and one of the most respected names in the cannabis industry - points out that this was always the plan: to grow Juva Life with recreational operations before expanding into broader life sciences as the company’s ground-breaking research uncovers the true medical potential of cannabis.

The final piece of the puzzle - now in action - is Juva Life’s extensive ‘research registry’.

This is essentially a database of users who will test various iterations of certain products against each other and against other products already on the market.

In short, it means Juva Life can quickly and effectively extrapolate a huge amount of real-world data that can be used to advance research and help in evidencing claims of efficacy for molecules like JUVA-019 and JUVA-41. 

And all this can be done at a fraction of the time, cost, and risk of the traditional product development pathway. It all adds up to what could be a very exciting ride over the coming months for Juva Life.

Chloupek’s endgame: buyout or licensing, it’s win-win

Investors might also be interested to learn that Chloupek’s endgame is NOT for Juva Life to focus heavily on the commercialization of molecules like JUVA-019 and JUVA-041 itself.

He wants to either attract a significant buyout in the next 24 months to issue multiple licenses to pharmaceutical or life sciences firms that will use its patented molecules in their own applications.

With all this in mind, JuvaLife could be one of the most exciting plays around right now. But with the word starting to get out, it won’t be long before other investors start to notice – so make sure you don’t miss out.

Read our free report to find out why you should invest in Juva Life right now before the wider market learns of its game-changing discoveries.

.

Company Info

Founded by pioneers in the science and business of cannabis and guided by a team of highly-acclaimed medical professionals, Juva Life brings unprecedented depth of knowledge in the science and medicinal effects of cannabis.

Exchange / Symbol
CSE:JUVA
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

Company Info

Founded by pioneers in the science and business of cannabis and guided by a team of highly-acclaimed medical professionals, Juva Life brings unprecedented depth of knowledge in the science and medicinal effects of cannabis.

Exchange / Symbol
OTCQB:JUVAF
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

Read our free report to find out why you should invest in Juva Life right now before the wider market learns of its game-changing discoveries.

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Juva Life JL002 to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred and sixteen thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.